Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma
Conditions
- Aggressive Non-Hodgkin Lymphoma
- ALK-Positive Large B-Cell Lymphoma
- Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements
- High Grade B-Cell Lymphoma, Not Otherwise Specified
- Primary Mediastinal Large B-Cell Lymphoma
- T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
- Gray-Zone Lymphoma
Interventions
- DRUG: Polatuzumab Vedotin
- BIOLOGICAL: Rituximab
- DRUG: Prednisone
- DRUG: Etoposide
- DRUG: Doxorubicin
- DRUG: Cyclophosphamide
- BIOLOGICAL: Glofitamab
- PROCEDURE: Multigated Acquisition Scan
- PROCEDURE: Echocardiography Test
- PROCEDURE: FDG-Positron Emission Tomography
- PROCEDURE: Computed Tomography
- PROCEDURE: Bone Marrow Biopsy
- PROCEDURE: Biospecimen Collection
- PROCEDURE: Bone Marrow Aspiration
Sponsor
University of Washington
Collaborators